Myeloperoxidase

Preempting Coronary Ischemia – Expanding the Spectrum of Cardiac Biomarkers

 

MPO testing provides prognostic information in addition to troponin and hsCRP testing, revealing a more complete clinical picture of the CVD patient. It may also add incremental value when used with other biomarkers, particularly in troponin-negative patients, enabling treatment before more severe myocardial damage occurs.


Learn more about MPO


Reliable Answers to Critical Cardiac Questions
As a recognized worldwide leader in CVD testing, Siemens Healthcare Diagnostics offers MPO testing across multiple instrument solutions to help provide a more complete clinical picture of the CVD patient.


Features:

  • Fully automated, no-pretreatment MPO
  • Can be run on same instrument along with other cardiac markers
  • Same turnaround time as troponin


Myeloperoxidase assays are available on the following systems from Siemens Healthcare Diagnostics:

Integrated Systems


Share this page:

Related Products, Services & Resources